- Home
- WWR vs MREO Comparison
WWR vs MREO Comparison
Compare WWR & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WWR | MREO |
|---|---|---|
| Founded | 1977 | 2015 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Metal Mining | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 53.4M | 50.3M |
| IPO Year | 2006 | 2017 |
Fundamental Metrics
Financial Performance| Metric | WWR | MREO |
|---|---|---|
| Price | $0.42 | $0.29 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 8 |
| Target Price | ★ $2.17 | $1.97 |
| AVG Volume (30 Days) | 683.7K | ★ 833.4K |
| Earning Date | 11-11-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 16.67 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $500,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.38 | $0.20 |
| 52 Week High | $1.51 | $2.37 |
Technical Indicators
Market Signals| Indicator | WWR | MREO |
|---|---|---|
| Relative Strength Index (RSI) | 37.85 | 42.53 |
| Support Level | $0.39 | $0.27 |
| Resistance Level | $0.45 | $0.35 |
| Average True Range (ATR) | 0.02 | 0.02 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 45.04 | 13.95 |
Price Performance
Historical ComparisonAbout WWR Westwater Resources Inc.
Westwater Resources Inc is an energy technology company focused on developing battery-grade natural graphite materials through a vertically integrated, mine-to-market strategy anchored by its two primary projects in Coosa County, Alabama: the Kellyton Graphite Plant and the Coosa Graphite Deposit. Westwater also holds mineral rights to explore and mine the Coosa Graphite Deposit, which Westwater anticipates will eventually provide natural graphite flake concentrate as feedstock to the Kellyton Graphite Plant.
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat, mainly for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).